BNP Paribas Financial Markets Has $6.59 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

BNP Paribas Financial Markets boosted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report) by 323.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,544 shares of the company’s stock after purchasing an additional 63,067 shares during the quarter. BNP Paribas Financial Markets owned about 0.17% of Axsome Therapeutics worth $6,587,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Washington Trust Advisors Inc. acquired a new position in Axsome Therapeutics during the fourth quarter worth about $26,000. Janiczek Wealth Management LLC acquired a new position in Axsome Therapeutics during the first quarter worth about $97,000. SG Americas Securities LLC acquired a new position in Axsome Therapeutics during the fourth quarter worth about $170,000. Neo Ivy Capital Management acquired a new position in Axsome Therapeutics during the third quarter worth about $204,000. Finally, DAVENPORT & Co LLC acquired a new position in Axsome Therapeutics during the fourth quarter worth about $304,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $82.50 on Thursday. The stock has a market capitalization of $3.92 billion, a PE ratio of -12.93 and a beta of 1.26. Axsome Therapeutics, Inc. has a one year low of $55.02 and a one year high of $98.40. The business’s 50 day simple moving average is $76.36 and its 200 day simple moving average is $79.17. The company has a debt-to-equity ratio of 1.25, a current ratio of 3.20 and a quick ratio of 3.09.

Axsome Therapeutics (NASDAQ:AXSMGet Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.11. The firm had revenue of $75.00 million for the quarter, compared to analysts’ expectations of $69.91 million. Axsome Therapeutics had a negative return on equity of 87.17% and a negative net margin of 118.07%. As a group, research analysts forecast that Axsome Therapeutics, Inc. will post -4.7 earnings per share for the current year.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 7,910 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total transaction of $587,792.10. Following the transaction, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $429,734.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Mark Coleman sold 5,249 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $75.21, for a total transaction of $394,777.29. Following the transaction, the director now directly owns 19,848 shares of the company’s stock, valued at $1,492,768.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Mark L. Jacobson sold 7,910 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total value of $587,792.10. Following the transaction, the chief operating officer now directly owns 5,783 shares in the company, valued at $429,734.73. The disclosure for this sale can be found here. Company insiders own 22.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on AXSM shares. Royal Bank of Canada boosted their target price on Axsome Therapeutics from $127.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 5th. Truist Financial restated a “buy” rating and set a $150.00 price target on shares of Axsome Therapeutics in a report on Tuesday, March 26th. HC Wainwright restated a “buy” rating and set a $190.00 price target on shares of Axsome Therapeutics in a report on Thursday, June 6th. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a report on Wednesday, April 10th. Finally, Robert W. Baird boosted their price target on Axsome Therapeutics from $108.00 to $112.00 and gave the stock an “outperform” rating in a report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $122.08.

Read Our Latest Stock Report on Axsome Therapeutics

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Recommended Stories

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.